2 February 2018 - After years of preparation, the EU unveiled plans for greater health technology assessment harmonisation this week – and put the potential benefits for life sciences centre stage
The vision of medicines and medical devices moving towards a single EU health technology appraisal took one step closer to reality this week – and the pharma industry welcomed it.
While the European Union has had a single centralised approval for new medicines since 2004, health technology assessment has remained a matter for member states, reflecting its use in deciding national pricing and reimbursement and market access decisions.